GPCR Technology

CALIXAR conducts intensive internal research efforts on all families of membrane proteins.

The production of the GPCR targets listed below is currently being optimized in our labs and some of them are already available in our catalogue for research purposes only.

For all developments related to drug / biodrug discovery as well as antibody discovery, an exclusive or non-exclusive license must be set up.



Adenosine receptor A2A

Good therapeutic candidate for insomnia, pain, depression, drug addiction and Parkinson’s disease.


CX3C chemokine receptor 1

Involved in the adhesion and migration of leukocytes and also is a coreceptor for HIV-1.

Good therapeutic candidate for Alzheimer’s disease and other neurological disorders.


Glucagon-like peptide 2 receptor

GPCR involved in intestinal growth and formation by promoting regeneration of the epithelial surface of the gut and thus is an obvious therapeutic target in the field of gastrointestinal diseases.

Good candidate for neurological disorders and diabetes.


Muscarinic acetylcholine receptor M1

Like the other muscarinic receptors, its mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins.

Good therapeutic candidate for Schizophrenia and Alzheimers.


Melatonin receptor 1

GPCR that modulates neuronal firing, arterial vasocon-striction, cell proliferation in cancer cells, and reproductive and metabolic functions.

Good therapeutic candidate for insomnia, circadian sleep disorders, depression, cardiovascular regulation, cancer and neurodegenerative diseases.


Melatonin receptor 2

GPCR found primarily in the retina and brain.

Good therapeutic candidate for melatonin dependent neurobiological dysfunction and diabetes.


Orphan G-protein coupled receptor

Homologous to odorant GPCR.

Good candidate for cancer treatment.